Hepatitis C (genotype 1) - telaprevir (TA252)
NICE recommends telaprevir with peginterferon alfa and ribavirin as a possible treatment for genotype 1 chronic hepatitis C in adults with the earlier stages of liver disease (known as compensated liver disease).
Who can have telaprevir?
You should be able to have telaprevir with peginterferon alfa and ribavirin if:
- you have not been treated for genotype 1 chronic hepatitis C before, or
- you have had pegylated or non-pegylated interferon alfa (with or without ribavirin) but the treatment did not work well enough.
Why has NICE said this?
NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE recommended telaprevir because it works better than other treatments available on the NHS. Although it also costs more than other treatments, this was justified by the benefits it provided.
This page was last updated: 10 January 2014
- Web format
- Full Guidance (PDF)
- TA252 Telaprevir ar gyfer hepatitis C cronig genoteip 1: deall canllawiau NICE (fformat MS Word)
Information for the public
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.